Overview
Sponsored by the American College of Chest Physicians.
Supported by an unrestricted educational grant from GlaxoSmithKline.
Program Description
COPD is the fourth leading cause of chronic morbidity and mortality in the United States. Its prevalence and impact are increasing, and The World Bank and the World Health Organization have projected it will rank fifth in 2020 as a global burden of disease. The economic and public health impact of COPD is staggering, because this chronic condition requires long-term care, frequent office visits, and the use of ED and hospital services. This session will provide an update on COPD based on the current literature and a review of the results of new clinical trials, with an emphasis on the pressing need for new therapies that control symptoms and prevent disease progression. Pharmacologic and nonpharmacologic measures will be presented to define how clinicians can best improve quality of care, with smoking cessation mandatory for all patients to slow the progression of lung function loss. New areas of research that may help guide COPD management in the future will be presented, as well.
In this web-based format, participants have the opportunity to obtain the information as it was originally presented by watching the video slide presentations on line, downloading the slides for review, or downloading a written executive summary of the presentations to read. Following their review of the presentations, participants will be asked relevant test questions as part of the evaluation process to obtain CME credit.
Educational Objectives
Following the symposium, participants will be able to:- Discuss important factors that may alter disease progression in COPD.
- Understand current pharmacologic and nonpharmacologic therapies for COPD, outlining the results of recent clinical trials.
- Discuss the role of disease management, including self-management programs.
- Describe novel targets of therapy, outlining future research needs.
Target Audience
Advanced Practice Nurses, Cardiologists, Critical Care Physicians, Fellows-in-Training, General Medicine Physicians, Physician Assistants, Pulmonary Physicians, Registered Nurses, and Respiratory Therapists.
Needs Assessment
In 2004, 11.4 million US adults (aged 18 and older) were estimated to have COPD. However, close to 24 million US adults have evidence of impaired lung function, indicating an underdiagnosis of COPD.1 An estimated 638,000 hospital discharges were reported; the discharge rate was 21.8 per 100,000 populations. COPD is an important cause of hospitalization in our aged population. Approximately 65% of discharges were for people 65 years and older in 2004.2
Early diagnosis and effective treatment in the milder stages of COPD are vital in preventing complications and worsening of symptoms over time. Although spirometry is the most accurate method to confirm the diagnosis of COPD and establish the treatment plan, two-thirds of patients at risk for COPD do not receive a spirometry exam. Moreover, the majority of patients with COPD are being diagnosed solely on symptoms and smoking history. Many patients are undertreated or overtreated compared with guideline recommendations. A screening questionnaire for COPD is available that can improve the identification of patients at risk for COPD. This screening tool can assist the primary care physician with identifying potential patients with COPD in a busy office practice.
COPD is important to the members of the ACCP, as most of our members treat these diseases everyday. The ACCP has included COPD in the core curriculum that is being developed to guide the ACCP in its educational offerings. Moreover, the ACCP CHEST 2008 Program Committee named COPD as one of the key topics to be covered at the CHEST 2008 annual meeting.
References
- 1. National Center for Health Statistics. National Health Interview Survey, 2004
- 2. National Heart, Lung, and Blood Institute, Morbidity and Mortality Chartbook, 2004
Faculty
Nicola A. Hanania, MBBS, FCCP
Associate Professor of Medicine
Section of Pulmonary and Critical Care Medicine
Director, Asthma Clinical Research Center
Baylor College of Medicine
Houston, TX
Sandra G. Adams, MD, FCCP
Associate Professor of Medicine
Division of Pulmonary Diseases/Critical Care Medicine
The University of Texas Health Science Center at San Antonio
Staff Physician, South Texas Veterans Health Care System
Mario Cazzola, MD, FCCP
Professor of Respiratory Medicine
University of Rome Tor Vergata
Department of Internal Medicine
Rome, Italy
Kenneth R. Chapman, MD, MS, FCCP
Professor of Medicine
University of Toronto
Director, Asthma and Airway Centre
University Health Network
Toronto, ON, Canada
CME & Disclaimers
Release: May 2009
CME Expiration: June 30, 2010
Estimated completion time: 2 hours
This CME product is a Web-based activity.
Participants will watch and listen to a Webcast slide presentation and complete an activity evaluation to obtain CME.
Accreditation/Designation
The American College of Chest Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American College of Chest Physicians designates this educational activity for a maximum of 2 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Anyone who attended the COPD 2009 morning symposium session at CHEST 2008 when this content was originally presented, and already claimed CME for this presentation, cannot claim CME from this enduring product.
Disclosure Statement
The ACCP remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of the ACCP to eliminate all situations of potential conflict of interest, but rather to enable those who are working with the ACCP to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the educational activity course director/chair, the Education Committee, or the Conflict of Interest Review Committee to ensure that such situations are properly evaluated and, if necessary, resolved. The ACCP educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all ACCP CME activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available on-site during all educational activities.
The following faculty members of this educational activity have disclosed to the ACCP that a relationship does exist with the respective company/organization as it relates to their presentation of material and should be communicated to the participants of this educational activity:
Sandra G. Adams, MD, FCCP
Grant monies (from sources other than industry): Veterans Administration, National Institute of Health
Grant monies (from industry related sources): Bayer Pharmaceutical, Schering-Plough, Boehringer Ingelheim Pharmaceutical, GlaxoSmithKline, Pfizer, Novartis, Centocor
Other (honoraria for speaking): ABComm, Altana, AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, and Schering-Plough
Product/procedure/technique that is considered research and is NOT yet approved for any purpose: All of the medications that I will be discussing are FDA approved, but not for the purposes that I will be discussing. Only one of the medications for COPD is approved for the prevention of acute exacerbations of COPD, and none are approved for slowing the progression of COPD. I will be discussing the data supporting these outcomes.
Mario Cazzola, MD, FCCP
Grant monies (from industry related sources): Travel grants from Boehringer Ingelheim, Novartis, AstraZeneca, Menarini
Fiduciary position (of any organization, association, society, etc, other than ACCP: At the present time, Secretary, Inflammatory Airways Diseases and Clinical Allergy Assembly. From October 2008, Director of Postgraduate Courses at European Respiratory Society, Scientific Bureau of Società Italiana di Medicina Respiratoria.
Consultant fee, speaker bureau, advisory committee, etc: Advisory committee of Nycomed (Altana), advisory committees of GSK, Novartis, and Dey; speaker bureau of Novartis
Product/procedure/technique that is considered research and is NOT yet approved for any purpose: Drugs to be used in the treatment of COPD that are still in development
Kenneth R. Chapman, MD, FCCP
Grant monies (from industry related sources): AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Novartis, Nycomed, Schering, ZLB Behring, Talecris, Baxter
Consultant fee, speaker bureau, advisory committee, etc: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Novartis, Nycomed, Schering, ZLB Behring, Talecris
Nicola A. Hanania, MBBS, FCCP
Grant monies (from sources other than industry); NIH, American Lung Association
Grant monies (from industry related sources): Boehringer Ingelheim, Dey Inc, GSK, Sepracor, Altana
Consultant fee, speaker bureau, advisory committee, etc: GSK, Sepracor, Boerhinger Ingelheim, Altana
Disclaimer
The American College of Chest Physicians ("ACCP") and its officers, regents, executive committee members, members, related entities, employees, representatives and other agents (collectively, "ACCP Parties") are not responsible in any capacity for, do not warrant and expressly disclaim all liability for, any content whatsoever in any ACCP publication or other product (in any medium) and the use or reliance on any such content, all such responsibility being solely that of the authors or the advertisers, as the case may be. By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any ACCP publication or other product. Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the ACCP Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
CME Instructions
CME for this activity is available through June 30, 2010. To receive CME credit and print your certificate, complete an online evaluation by doing the following:
- Go to www.chestnet.org, and click on the "CME Certificates" icon.
- Log in using your ACCP ID number or e-mail address on file with the ACCP. Enter your ACCP ID number and click submit, OR, if you do not have an ACCP ID number, click on the link, "Create an account here."
- To locate the product for which you want to claim CME credit, look under the "Available CME" tab on the left navigation bar.
- Click the "Claim Credit" link next to the product to begin the certificate process.
- Complete any required posttest and evaluation. Please be sure to check the box that states you are finished with the evaluation.
- Once you submit the evaluation, your CME certificate will be created and will show under the tab, "My CME History." You can print it at any time by clicking the "Certificate" link.
If you need help, please contact the CME Administrator via e-mail at CME@chestnet.org, or leave a voice mail message at (847) 498-8376. For faster assistance, please outline the specific problem you are having, and provide your ACCP ID and contact information.
Search Archives
Search the ACCP archives for CME and non-CME related material. To see our entire archive put a * in the field below and hit search.
Submit Feedback
The ACCP is interested in your feedback concerning A Physician's Perspective®.
